Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2013-01-01
2019-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TTC patients with hyperglycemia
These patients will be hospitalized for TTC acute event. These patients will be characterized by higher blood glucose values at admission, and so defined as hyperglycemics.
To report number of HF events and deaths
In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
TTC patients with normoglycemia
These patients will be hospitalized for TTC acute event. These patients will be characterized by normal blood glucose values at admission, and so defined as normoglycemics.
To report number of HF events and deaths
In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
To report number of HF events and deaths
In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* cardiac biomarker modifications (creatine kinase-MB and troponin I);
* systolic dysfunction, predominantly characterized by akinesia/hypokinesia of the mid-to-distal portion of the left ventricle (LV) chamber, with hyper-contractile basal LV.
Exclusion Criteria
* patients with previous TTC event;
* patients affected by chronic kidney, liver, and cerebrovascular diseases.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Campania Luigi Vanvitelli
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Celestino Sardu
researcher
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Raffaele Marfella
Naples, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Paolisso P, Bergamaschi L, Rambaldi P, Gatta G, Foa A, Angeli F, Fabrizio M, Casella G, Barbieri M, Galie N, Marfella R, Pizzi C, Sardu C. Impact of Admission Hyperglycemia on Heart Failure Events and Mortality in Patients With Takotsubo Syndrome at Long-term Follow-up: Data From HIGH-GLUCOTAKO Investigators. Diabetes Care. 2021 Sep;44(9):2158-2161. doi: 10.2337/dc21-0433. Epub 2021 Jun 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02.12.20
Identifier Type: -
Identifier Source: org_study_id